Objective: This study aims to show the Incidence of Radiation-Induced Proctitis and Cystitis on MRI among Post-Radiotherapy Patients at B.P Koirala Memorial Cancer Hospital.

Materials and Methods: A total of 139 cervical cancer patients who received radiation therapy at B.P Koirala Memorial Cancer Hospital from February 2025 - May 2025 who met the inclusion criteria are included in this study. Factors assessed included age, history of radical hysterectomy surgery and duration of radiation. Moreover, different cystitis and Proctitis features are noted for the analysis. DWI/ADC can also use distinguish active inflammation (restricted diffusion) from chronic fibrosis (low signal, no restriction), and wall thickness is measured using software tools.

Results: A total of 139 cervical cancer patients who received radiation therapy at BPKMCH during the study period were included in the analysis. The patients’ ages ranged from 25 to 78 years, with a mean age of 52.17 ± 11.73years. Age-wise distribution showed the highest number of patients in the 50-60 years age group. Radiation-induced cystitis occurred in 18 patients, corresponding to 13% of the cohort. Among these, mean thickness was 5.11 mm while minimum and maximum was 4 mm and 6 mm respectively with S.D of 0.75. Radiation-induced Proctitis was observed in 43 patients, representing 31% of the study population. Among these, mean thickness was 7.55 mm while minimum and maximum was 5 mm and 11 mm respectively with S.D of 1.42.

Conclusion: Radiation-induced Proctitis and cystitis remain significant complications of pelvic radiotherapy for cervical cancer. MRI plays an essential role in early detection, severity assessment, and differentiation from other pathologies, supporting timely intervention and improved patient care.

Keywords: Radiation; Cystitis; Proctitis; MRI; BPKMCH

References

1. Arsalan HM., et al. “Prospective biochemical analysis of chronic myeloid leukemia patients in response to tyrosine kinase inhibitors”. Pakistan Journal of Zoology5 (2023): 2103-2111.
2. Massimino M., et al. “Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia”. Molecular Cancer1 (2018): 56.
3. Hochhaus A., et al. The New England Journal of Medicine10 (2017): 917.
4. Arsalan HM., et al. “Tracking Molecular Response of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia Patients Using RT-PCR Profiling of BCR-ABL Transcripts”. Chelonian Conservation and Biology2 (2023): 1174-1186.
5. Kalmanti L., et al. “Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV”. Annals of Hematology1 (2014): 71-80.
6. Irwin ME., et al. “A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies”. Oncotarget 27 (2001): 23631.
7. Faiza M., et al. “Pre and post treatment effect of imatinib and anti-oxidant status in chronic myeloid leukemia Patients”. Journal of Population therapeutics & Clinical Pharmacology 5 (2024): 1391-1401.
8. Hughes TP and Shanmuganathan N. “Management of TKI-resistant chronic phase CML”. Hematology 1 (2022): 129-137.
9. Kantarjian HM., et al. “Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis”. Cancer 97 (2003): 1033-1041.
10. Lavallade HD., et al. “Imatinib for Newly Diagnosed Patients with Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis”. Journal Of Clinical Oncology Original Report20 (2008).
11. Goldman JM. “Treatment strategies for CML. & Research”. Clinical Haematology 22 (2009): 303-313.
12. Loscocco F., et al. “BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia”. Frontiers in Oncology 9 (2019): 939.
13. Jiye A., et al. “Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses”. PLoS ONE10 (2010): 13186.
14. Gladwin MT and Wang X. “Methodological vexation about thiol oxidation versus S-nitrosation-a commentary on “An ascorbate-dependent artifact that interferes with the interpretation of the biotin switch assay”. Free Radical Biology and Medicine4 (2006): 557-561.
15. Spitz DR and Oberley LW. “Measurement of Mn-SOD and Cu-Zn-SOD activity in mammalian tissue homogenates”. Current Protocol Toxicology 8 (2001): 7.5.1-7.5.11.
16. Weydert JC and Cullen JJ. “Measurement of Superoxide Dismutase, Catalase and Glutathione Peroxidase in cultured cells and tissue”. Nature Protocols1 (2011): 51-66.
17. Khazaal MS., et al. “Association of BCR/ ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients”. Molecular Genetics and Genomic Medicine 7 (2019): e809.
18. Kim TD., et al. “Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib”. Leukemia 6 (2013): 1316-1321.
19. Geelen IG., et al. “Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects”. Annals of Hematology 6 (2023): 1395-1408.
20. Bilajac E., et al. “Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines”. Metabolites 11 (2022): 58.
21. Dong C., et al. “Oxidative stress in leukemia and antioxidant treatment”. Chinese Medical Journal 16 (2021): 1897-1907.
22. Ahmed AA., et al. “Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features”. Bionatura3 (2022): 41.
23. Donne DI., et al. “Protein carbonylation, cellular dysfunction, and disease progression”. Journal of Cellular and Molecular Medicine 2 (2006): 389-406.
24. Ren X., et al. “Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors”. Annals of Hematology 98 (2019): 1627-1640.
25. Kuan JW., et al. “The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island”. Medical Journal of Malaysia 73 (2018): 78-85.

Citation

Citation: Shivaji Poudel., et al. “Incidence of Radiation-Induced Cystitis and Proctitis on MRI among Post-Radiotherapy Patients at BPKMCH".Acta Scientific Cancer Biology 9.4 (2025): 12-19.

Copyright

Copyright: © 2025 Shivaji Poudel., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.